Topic: shareholder activism
Bayer Chairman Werner Baumann could face a vote a no confidence from its top investor, BlackRock, Reuters reported.
Allergan has been warring with investors pushing for a change to the company's leadership structure, but leading proxy adviser firms aren't on board.
Proxy adviser Glass Lewis opposes re-electing Marcus Wallenberg, a member of Sweden's powerful Wallenberg family.
Recommendations to vote “yes” from proxy advisory firms were enough to end an activist’s efforts to scuttle the BMS-Celgene merger.
When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up.
Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.
What's Bristol-Myers' Plan B if its Celgene deal falls through? The company won't say whether it has one, much less what it might be.
After Allergan revealed a major pipeline prospect had flunked in phase 3, analysts predicted activists would ramp up pressure on execs. And they did.
A major Allergan pipeline candidate may have failed a pivotal trial, but investors cheered the news. The reason? They’re anticipating a company split.
AstraZeneca CEO Pascal Soriot pulled in nearly $15 million in 2018 compensation as the company works to return to growth.